BRIEF

on AMOEBA (EPA:ALMIB)

AMOÉBA Confirms Development Potential in Cosmetics Sector

Stock price chart of AMOEBA (EPA:ALMIB) showing fluctuations.

AMOÉBA, a greentech company based in Chassieu, France, has announced positive results from a clinical study involving its cosmetic ingredient. Conducted by the Institut d'Expertise Clinique, the study involved 30 volunteers and verified significant improvements in skin care attributes, including dermis thickness, dermal texture, and skin density.

This follows an earlier announcement in October 2023, where tests on artificial skin showed promising outcomes, prompting AMOÉBA to explore cosmetic applications further. The company's active ingredient has now been included on the International Nomenclature for Cosmetic Ingredients (INCI) list, facilitating market entry without additional regulatory approvals.

AMOÉBA will present its strategy at the Portzamparc BNP Paribas Group Conference in Paris on June 12. The presentation will be available on the company’s website by June 11.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all AMOEBA news